Earnings summaries and quarterly performance for ALX ONCOLOGY HOLDINGS.
Executive leadership at ALX ONCOLOGY HOLDINGS.
Board of directors at ALX ONCOLOGY HOLDINGS.
Research analysts who have asked questions during ALX ONCOLOGY HOLDINGS earnings calls.
Allison Bratzel
Piper Sandler Companies
3 questions for ALXO
Also covers: ABCL, AKBA, ARDX +7 more
Sam Slutsky
LifeSci Capital, LLC
3 questions for ALXO
Also covers: KYMR, PVLA, RAIN +1 more
DB
Daniel Braun
Cantor Fitzgerald
2 questions for ALXO
N
Nabil
Jefferies
2 questions for ALXO
RS
Ramakanth Swayampakula
H.C. Wainwright & Co., LLC
2 questions for ALXO
Also covers: AEMD, CORT, HUMA +2 more
LW
Li Wang Watsek
Cantor Fitzgerald
1 question for ALXO
Also covers: AFMD, ARVN, ASND +7 more
RS
Roger Song
Jefferies
1 question for ALXO
Also covers: AADI, AKBA, ALT +14 more
TL
Ting Liu
UBS Group
1 question for ALXO
Also covers: ABOS
YH
Yu He (Arthur)
H.C. Wainwright & Co., LLC
1 question for ALXO
Also covers: AUPH, NKTR
Recent press releases and 8-K filings for ALXO.
ALX Oncology Provides Updates on Oncology Pipeline and Funding
ALXO
New Projects/Investments
Guidance Update
- ALX Oncology is advancing two key oncology programs: evorpacept, a novel CD47 treatment, and ALX2004, an EGFR-targeted antibody-drug conjugate (ADC).
- The company recently completed a $150 million financing, which provides funding through the first half of 2028 to support program milestones.
- Key upcoming milestones include top-line data from 80 patients in the ASPEN breast study for evorpacept by mid-2027 and safety data for ALX2004 in the second half of 2026.
- Evorpacept has demonstrated promising clinical efficacy, with response rates of 65% in the ASPEN-06 study and 56% in combination with zanidatamab for HER2-positive breast cancer patients.
- ALX aims to have both evorpacept and ALX2004 programs pivotal-ready by the end of 2027.
4 days ago
ALX Oncology Provides Update on Clinical Programs and Financial Position
ALXO
New Projects/Investments
Guidance Update
- ALX Oncology is advancing two novel treatments in oncology: evorpacept (EVO), a CD47 inhibitor, and ALX2004, an EGFR-targeted ADC.
- Evorpacept has demonstrated promising clinical activity, including a 65% response rate in the ASPEN-06 study for HER2-positive breast cancer patients with CD47 overexpression and a 56% response rate in combination with zanidatamab in HER2-positive patients. The ongoing ASPEN breast study (ASPEN-09) is enrolling patients, with top-line data from 80 patients expected in mid-2027.
- ALX2004 is currently in dose escalation, with safety data anticipated in the second half of 2026.
- The company recently completed a financing of $150 million, which funds operations through the first half of 2028 and supports the goal of having both programs pivotal-ready by the end of 2027.
4 days ago
ALX Oncology Provides Update on Clinical Programs and Financial Position
ALXO
Guidance Update
New Projects/Investments
- ALX Oncology recently raised $150 million in financing, which is expected to fund the company through the first half of 2028.
- The company's lead program, evorpacept, a novel CD47 treatment, is focused on the ASPEN breast study for HER2-positive breast cancer, with top-line data from 80 patients expected in mid-2027.
- ALX Oncology is also advancing ALX2004, an EGFR-targeted ADC, in dose escalation, with safety data anticipated in the second half of 2026.
- The company aims to have both evorpacept and ALX2004 programs pivotal-ready by the end of 2027.
4 days ago
ALX Oncology Holdings Details Program Milestones and Cash Runway
ALXO
New Projects/Investments
Guidance Update
- ALX Oncology Holdings projects its cash runway to extend through the first half of 2028, supported by $150 million gross proceeds from a February 2026 financing.
- The company anticipates topline data for 80 patients from its evorpacept ASPEN-Breast program (ENHERTU®-Experienced HER2-Positive Breast Cancer) in mid-2027. This program targets a potential $2-4 billion market opportunity in CD47-high, HER2+ 2L+ breast cancer.
- For its ALX2004 program, targeting EGFR-Expressing Solid Tumors, safety data from the dose escalation phase is expected in the second half of 2026.
5 days ago
ALX Oncology Holdings Announces Q4 and FY 2025 Results, Clinical Updates, and Permanent CMO Appointment
ALXO
Earnings
Guidance Update
Management Change
- ALX Oncology Holdings reported a GAAP net loss of $22.8 million or $0.42 per basic undiluted share for Q4 2025.
- Following a recent $150 million financing (net proceeds of $140.4 million), the company expects its cash and investments to fund operations through the first half of 2028.
- Key clinical updates include impressive response rates for Evorpacept in HER2-positive gastric cancer, with a 65% response rate in CD47 overexpressing tumors, reported in November 2025. Further biomarker analysis from the evorpacept and zanidatamab breast cancer trial is expected in Q2 2026.
- Top-line data for 80 patients from the Phase II ASPEN-09-Breast trial for Evorpacept is anticipated in mid-2027, and full safety data for ALX2004 from the dose escalation phase is expected in the second half of 2026.
- Dr. Barbara Klencke has been appointed as the permanent Chief Medical Officer, having joined in an interim capacity in September 2025.
8 days ago
ALX Oncology Holdings Reports Q4 2025 Results, Strengthens Balance Sheet, and Provides Clinical Program Updates
ALXO
Earnings
Guidance Update
Management Change
- ALX Oncology reported a GAAP net loss of $22.8 million or $0.42 per basic undiluted share for the three months ended December 31, 2025, compared to a GAAP net loss of $29.2 million or $0.55 per share for the same period in 2024.
- The company successfully completed a recent financing, resulting in net proceeds of $140.4 million, which has strengthened its balance sheet and is expected to fund operating expenses through the first half of 2028.
- Dr. Barbara Klencke has been appointed as the permanent Chief Medical Officer, having been instrumental in driving development programs forward since joining in an interim capacity in September 2025.
- Clinical development for both Evorpacept and ALX2004 remains on track, with the goal to advance both programs to pivotal studies by the end of 2027.
- Key upcoming milestones include the full biomarker analysis readout for Evorpacept in HER2-positive breast cancer in Q2 2026, ALX2004 safety data from the dose escalation phase in the second half of 2026, and Evorpacept top-line data from the ASPEN-09-Breast trial in mid-2027.
8 days ago
ALX Oncology Holdings Reports Q4 2025 Results, Strengthens Balance Sheet, and Provides Clinical Program Updates
ALXO
Earnings
Guidance Update
New Projects/Investments
- ALX Oncology Holdings reported a GAAP net loss of $22.8 million or $0.42 per basic undiluted share for the three months ended December 31, 2025, an improvement from a GAAP net loss of $29.2 million or $0.55 per basic and diluted share for the same period in 2024.
- The company completed an equity financing in February 2026, generating $140.4 million in net proceeds, which is expected to fund operating expenses through the first half of 2028.
- Clinical development for Evorpacept is on track, with top-line data from the expanded Phase 2 ASPEN-09-Breast trial (now up to 120 patients) anticipated in mid-2027.
- The ALX2004 EGFR-targeted ADC program is progressing, with full safety data from the dose escalation phase of its Phase 1 trial expected in the second half of 2026.
- Dr. Barbara Klencke was appointed as the permanent Chief Medical Officer, having led clinical efforts in an interim capacity since September 2025.
8 days ago
ALX Oncology Reports Q4 and Full Year 2025 Financial Results and Provides Corporate Update
ALXO
Earnings
Guidance Update
New Projects/Investments
- ALX Oncology reported a GAAP net loss of ($22.8) million for Q4 2025 and ($101.7) million for the full year 2025. Following a $150 million registered offering in February 2026, with net proceeds of $140.4 million, the company's cash runway is extended through 1H 2028.
- Clinical development for evorpacept and ALX2004 remains on track, with the evorpacept biomarker strategy validated in gastric and breast cancer trials, and ALX2004 safety data expected in 2H 2026. Topline data for the Phase 2 ASPEN-09 breast cancer trial is anticipated in mid-2027.
- Barbara Klencke, M.D., was permanently appointed Chief Medical Officer.
8 days ago
ALX Oncology reports Q4 and FY 2025 results and provides clinical update
ALXO
Earnings
Guidance Update
New Projects/Investments
- ALX Oncology reported a GAAP net loss of $22.8 million for Q4 2025 and $101.7 million for FY 2025, both lower than the prior year periods; non-GAAP net loss was $20.1 million for Q4 and $88.8 million for FY 2025.
- Cash, cash equivalents, and investments totaled $48.3 million as of December 31, 2025; a $150 million equity offering in February 2026 extended the cash runway through 1H 2028.
- The company advanced its clinical pipeline, with key data readouts expected for evorpacept and ALX2004 in 2026 and 2027; the Phase 2 ASPEN-09 breast cancer trial is enrolling, and ALX2004’s Phase 1 trial is in the third dose cohort.
- Barbara Klencke, M.D., was appointed Chief Medical Officer on a permanent basis.
8 days ago
ALX Oncology Announces Pricing of Underwritten Offering
ALXO
New Projects/Investments
- ALX Oncology Holdings Inc. announced the pricing of an underwritten offering of 76,979,112 shares of common stock at $1.57 per share and 18,574,120 pre-funded warrants at $1.569 per pre-funded warrant.
- The offering is expected to generate approximately $150 million in gross proceeds before deductions and is anticipated to close on or about February 2, 2026.
- The net proceeds from the offering will be used to fund the continued clinical development of evorpacept and its ALX2004 program, related clinical trials, working capital, and other general corporate purposes.
- The financing is being led by new investors RA Capital Management and TCGX, with participation from additional new and existing investors.
Jan 30, 2026, 1:36 PM
Quarterly earnings call transcripts for ALX ONCOLOGY HOLDINGS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more